Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
The Journal of Infectious Diseases
|
June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 4, 2025
Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US
Pamela P Pei, Michelle Jones, Ruitian Hu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 17, 2018
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298
Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, et al.
AIDS (London, England)
|
November 7, 2015
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery
Anthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, et al.
Clinical and Translational Science
|
January 27, 2026
Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis
Nicholas M Smith, Brian M Ho, Katharine J Bar, et al.
The Journal of Infectious Diseases
|
February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes
Timothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Plos One
|
August 9, 2016
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects
Johannes S Gach, Andrea Gorlani, Emmanuel Y Dotsey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 10, 2021
Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV
Grant B Ellsworth, Elizabeth A Stier, Elizabeth Y Chiao, et al.
AIDS (London, England)
|
April 8, 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis
Rogers Sekabira, Ian McGowan, Krista Yuhas, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
The Journal of Infectious Diseases
|
June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 4, 2025
Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US
Pamela P Pei, Michelle Jones, Ruitian Hu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 17, 2018
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298
Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, et al.
AIDS (London, England)
|
November 7, 2015
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery
Anthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, et al.
Clinical and Translational Science
|
January 27, 2026
Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis
Nicholas M Smith, Brian M Ho, Katharine J Bar, et al.
The Journal of Infectious Diseases
|
February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes
Timothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
Plos One
|
August 9, 2016
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects
Johannes S Gach, Andrea Gorlani, Emmanuel Y Dotsey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 10, 2021
Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV
Grant B Ellsworth, Elizabeth A Stier, Elizabeth Y Chiao, et al.
AIDS (London, England)
|
April 8, 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis
Rogers Sekabira, Ian McGowan, Krista Yuhas, et al.
Page
of 7